NASDAQ:ECYT - Endocyte Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$23.99
+0.30 (1.20%)
Get New Endocyte Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ECYT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ECYT

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Endocyte in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $23.99.

This chart shows the closing price for ECYT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Endocyte. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/14/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/13/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/19/2018Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformLow
10/18/2018WedbushDowngradeOutperform ➝ NeutralLow
9/10/2018CowenReiterated RatingBuyHigh
8/2/2018Jefferies Financial GroupReiterated RatingBuy$21.00Low
7/16/2018WedbushBoost Price TargetOutperform ➝ Outperform$15.00 ➝ $21.00High
4/13/2018Jefferies Financial GroupInitiated CoverageBuy ➝ BuyHigh
3/9/2018Wells Fargo & CompanyInitiated CoverageOutperform ➝ OutperformHigh
2/27/2018CowenUpgradeMarket Perform ➝ OutperformHigh
10/3/2017WedbushUpgradeNeutral ➝ Outperform$2.00 ➝ $7.00High
10/2/2017CowenReiterated RatingHoldHigh
6/5/2017WedbushDowngradeOutperform ➝ Neutral$8.00 ➝ $2.00High
6/2/2017CowenDowngradeOutperform ➝ Market PerformLow
5/11/2017WedbushReiterated RatingOutperformHigh
4/5/2017CowenReiterated RatingBuyLow
(Data available from 12/9/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/13/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/12/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/12/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/11/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/10/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/10/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Endocyte logo
Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.
Read More

Today's Range

Now: $23.99
Low: $23.99
High: $23.99

50 Day Range

MA: N/A

52 Week Range

Now: $23.99
Low: $2.81
High: $24.00

Volume

N/A

Average Volume

2,117,754 shs

Market Capitalization

$1.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Endocyte?

The following Wall Street sell-side analysts have issued stock ratings on Endocyte in the last twelve months:
View the latest analyst ratings for ECYT.

What is the current price target for Endocyte?

0 Wall Street analysts have set twelve-month price targets for Endocyte in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Endocyte in the next year.
View the latest price targets for ECYT.

What is the current consensus analyst rating for Endocyte?

Endocyte currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ECYT.

How do I contact Endocyte's investor relations team?

Endocyte's physical mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company's listed phone number is 765-463-7175. The official website for Endocyte is www.endocyte.com.